Diabetes increases the risk of cardiovascular (CV) and renal disease (CVRD). These become major causes of mortality in individuals with diabetes. In this touchENDOCRINOLOGY interview, Prof. Peter Rossing (University of Copenhagen, Copenhagen, Denmark) discusses the relationship between cardiovascular and renal risks in diabetes
The abstract entitled: ‘Effect of semaglutide on MACE by baseline kidney function in participants with type 2 diabetes and high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc analysis’ was presented at the European Association for the Study of Diabetes, 19-23 Sept, 2022.
Questions:
- What is known about the relationship between cardiovascular and renal risks in diabetes? (0:18)
Disclosures: Peter Rossing is a consultant for Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Gilead, MSD, Novo Nordisk and Sanofi and discloses grant/research support from AstraZeneca and Novo Nordisk.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of EASD 2022
